Research and Markets (http://www.researchandmarkets.com/research/s6xvdg/global_oncology)
has announced the addition of the "Global
Oncology Market - Trends, Forecast and Pipeline Analysis"
report to their offering.
Cancer, with a death toll exceeding that of AIDS (Acquired Immune
Deficiency Syndrome), tuberculosis and malaria collectively, accounted
for 8.3 million deaths in 2013. With a skyrocketing incidence of 469.6
per 100,000 in the US alone, the oncology market is poised to grow at a
substantial CAGR of around seven percent to $109 billion by 2020.
Targeted therapy class is the top dog' among all therapy segments with
nearly 3x the combined market of cytotoxic and hormonal therapy. Growth
factors such as EGF (Epidermal Growth Factors) and VEGF govern around
half of the oncology therapy market, and have changed the landscape of
pipeline and LCM (Life Cycle Management) strategies, outstripping the
orthodox indications approach, said analyst Hardik Sharma. Although in
last two years, a plethora of targeted drugs has been launched and is in
development, price pressures have started popping up due to high
scrutiny from payers, physicians and governments.
With almost every drug growing annually above 10%, Roche is the market
leader and front-runner in life-cycle management of oncology drugs, as
it holds the highest number of in-line extensions (ILEs), which comprise
around half of its entire pipeline. The words of Roche CEO Severin
Schwan, We go where the science takes us demonstrates its focus on
bolt-on acquisitions compared with a transformational approach. Celgene
also shares the same philosophy as evident from its recent deal with
OncoMed.
Avastin is the leader with sales of $6.7 billion in 2013 and in the
short- to mid-term it is forecast to sustain its position supported by
its extensive pipeline and entrenched indications base. Meanwhile, in
the long term, Revlimid is expected to dominate due to its extensive
pipeline, prolonged patent term and impressive CAGR of more than 40%.
Key Topics Covered:
1. Charts & Tables
2. Market at a Glance - Global and Regional levels (NA, EU, APAC)
3. Introduction to Cancer (20 major cancers)
4. Market Overview
5. Global Oncology Market Forecast
6. Top Oncology Brands - Detailed Insight
7. Market Dynamics
8. Pipeline Analysis and Interpretation
9. Company Profiles
10. Competitive Landscape & Value Chain
11. Recent developments
12. Appendix
13. Research Methodology
14. Disclaimer
Companies Mentioned
- AbbVie
- Amgen
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
- Pfizer, Inc
- Sanofi S.A.
For more information visit http://www.researchandmarkets.com/research/s6xvdg/global_oncology
Copyright Business Wire 2014